- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06382480
Repas riches en PROTeIn pour contrôler le glucose (PROTIME)
Stratégies basées sur l'horaire des repas pour améliorer le métabolisme du glucose dans le prédiabète et le diabète de type 2
The overall aim is to identify the dietary pattern for prevention and treatment of type 2 diabetes. The specific aim of this pilot project is to compare effects of two diets with different diurnal distribution of carbohydrates and protein on the glucose metabolism in subjects with prediabetes and type 2 diabetes and its effects on inflammatory status.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Overweight individual with prediabetes and non-insulin treated type 2 diabetes will be recruited for the study. The trial will have a cross-over design and compare metabolic effects of two isocaloric 4-week interventions with opposite timely distribution of macronutrient intake - a high-protein (HP) breakfast and a high-carb (HC) dinner (HP/HC intervention) vs. a HC breakfast and a HP dinner (HC/HP intervention) - divided by a 4-week wash-out phase. A HP low-carb meal (breakfast or dinner) will contain 35%E protein, 35%E carbs, and 30%E fat, and a HC meal (breakfast or dinner) will contain 10E%protein, 60%E carbs, and 30%E fat.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Potsdam-Rehbrücke
-
Potsdam, Potsdam-Rehbrücke, Allemagne, 14558
- Olga Ramich
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Prediabetes (fasting blood sugar 100-125 mg/dl)
- Diabetes type 2 (fasting blood sugar >126 mg/dl)
- Overweight and obesity (BMI 25-50 kg/m2)
Exclusion Criteria:
- Other diabetes types
- Insulin treatment
- Shift work
- Weight changes >5% within past 3 months
- Systemic glucocorticoid therapy
- Systemic infections
- Severe anemia
- High blood pressure (>180/110 mmHg)
- Endocrinologic, liver and heart disorders
- Immune diseases
- Thyroid dysfunction
- Heart attack or stroke
- Cancer in the last 2 years
- Eating disorders, food intolerance/allergy, addiction disorders, digestive disorders intestinal, liver, cardiovascular diseases
- Hereditary or acquired coagulation disorders
- Non-interruptible intake of blood thinners (anticoagulants)
- Specific diets, intermittent fasting
- Pregnancy or breastfeeding
- Severe internal or psychiatric disorders or other conditions and drugs therapy that might influence the outcome of the study
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: HP/HC - HC/HP
Isocaloric 4-week HP/HC intervention followed by a 4-week HC/HP intervention. |
The intervention is about an isocaloric diet that differs in terms of distribution of carbohydrates and protein throughout the day. The interventions include a HP-breakfast and a HC-dinner vs. a HC-breakfast and a HP-dinner. A HP low-carb meal (breakfast or dinner) will contain 35%E protein, 35%E carbs, and 30%E fat, and a HC meal (breakfast or dinner) will contain 10%E protein, 60%E carbs, and 30%E fat. |
|
Expérimental: HC/HP - HP/HC
Isocaloric 4-week HC/HP intervention followed by a 4-week HP/HC intervention. |
The intervention is about an isocaloric diet that differs in terms of distribution of carbohydrates and protein throughout the day. The interventions include a HP-breakfast and a HC-dinner vs. a HC-breakfast and a HP-dinner. A HP low-carb meal (breakfast or dinner) will contain 35%E protein, 35%E carbs, and 30%E fat, and a HC meal (breakfast or dinner) will contain 10%E protein, 60%E carbs, and 30%E fat. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Mean 24-hour glucose
Délai: 4 weeks
|
Mean 24-hour glucose assessed by continuous glucose monitoring (CGM) |
4 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Measurement of height
Délai: 4 weeks
|
Height measured by stadiometer |
4 weeks
|
|
Measurement of body weight
Délai: 4 weeks
|
Body weight measured by body scale |
4 weeks
|
|
Waist and hip circumference / waist to hip ratio
Délai: 4 weeks
|
Waist and hip circumference measured by tape measure |
4 weeks
|
|
Systolic and diastolic blood pressure
Délai: 4 weeks
|
Systolic and diastolic blood pressure changes measurement by manometer |
4 weeks
|
|
Body fat and lean mass
Délai: 4 weeks
|
Body fat and lean mass assessed by bioelectrical impendance analysis (BIA) |
4 weeks
|
|
Energy expenditure and substrate oxidation rates
Délai: 4 weeks
|
Energy expenditure and substrate oxidation rates assessed by indirect calorimetry |
4 weeks
|
|
Hepatic values (gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT))
Délai: 4 weeks
|
GGT, AST, ALT etermined in fasting blood samples |
4 weeks
|
|
Renal values (creatinine, urea, uric acid)
Délai: 4 weeks
|
Renal values determined in fasting blood samples |
4 weeks
|
|
Intra- und inter-day glycemic variability
Délai: 4 weeks
|
Indices of intra- and inter-day glycemic variability assessed by continuous glucose monitoring (CGM) |
4 weeks
|
|
Glucose levels in meal tolerance test (MTT)
Délai: 4 weeks
|
Glucose levels in blood samples collected in MTT |
4 weeks
|
|
Metabolic hormones (insulin, C-peptide, glucagon, glucagon-like peptite 1(GLP-1), gastric inhibitory polypeptide (GIP), peptide YY (PYY), ghrelin, adiponectin, leptin)
Délai: 4 weeks
|
Blood levels of metabolic hormones assessed in fasting state and during the MTT |
4 weeks
|
|
Inflammatory markers and T cell populations analyses
Délai: 4 weeks
|
Level of the inflammatory markers IL-6, TNFa, MCP-1 and T cell populations in circulation and adipose tissue are assessed through blood analysis and fat biopsy |
4 weeks
|
|
Satiety and hunger scores
Délai: 4 weeks
|
Satiety and hunger scores assessed using Visual Analog Scale (VAS with a scale of 1-100, where higher values correspond to stronger satiety/hunger) |
4 weeks
|
|
Sleep/wake timing and sleep quality
Délai: 4 weeks
|
Sleep/wake timing and sleep quality assessed by the Pittsburgh Sleep Quality Index (PSQI score, which ranges from 0-21, where higher values correspond to worse sleep quality) and also monitored by an ActiGraph device |
4 weeks
|
|
Physical activity
Délai: 4 weeks
|
24-h physical activity will be monitored by an ActiGraph device |
4 weeks
|
|
Adipose tissue transcriptome
Délai: 4 weeks
|
RNA-Seq analysis of subcutaneous adipose tissue sample |
4 weeks
|
|
Gene expression in peripheral blood mononuclear cells (PBMC)
Délai: 4 weeks
|
Expression of metabolic genes assessed by qPCR |
4 weeks
|
|
Gut microbiota and microbiome-derived metabolites
Délai: 4 weeks
|
Determined in stool samples and blood plasma |
4 weeks
|
|
Determination of decision behavior
Délai: 4 weeks
|
Impulsiveness assessed by decision making tasks on computer |
4 weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Olga Ramich, PD Dr., German Institute of Human Nutrition
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système endocrinien
- Troubles nutritionnels
- Maladies métaboliques
- Suralimentation
- Poids
- Troubles du métabolisme du glucose
- Diabète sucré
- Conditions pathologiques, signes et symptômes
- Maladies nutritionnelles et métaboliques
- Signes et symptômes
- En surpoids
- Obésité
- Diabète sucré, Type 2
- État prédiabétique
- Régime, nourriture et nutrition
- Phénomènes physiologiques
- Phénomènes physiologiques nutritionnels
- Régime
Autres numéros d'identification d'étude
- 90/2023
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .